Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis

Pharmacological Research

Volumn 64, Issue 3, 2011, Pages 298-307

  Munić, Vesna ^a,b   Banjanac, Mihailo ^a   Koštrun, Sanja ^a   Nujić, Krunoslav ^a   Bosnar, Martina ^a   Marjanović, Nikola ^a   Ralić, Jovica ^a   Matijašić, Mario ^a   Hlevnjak, Mario ^a   Haber, Vesna Eraković ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Galapagos Istraživački Centar Doo ^*  (Croatia)

Author keywords

Cellular accumulation; Inflammation; J774A.1; Lipid binding; Macrolide; Macrophage; Phospholipidosis; Uptake

Indexed keywords

AMIODARONE; AZITHROMYCIN; CHLOROQUINE; CLARITHROMYCIN; DEXAMETHASONE; ERYTHROMYCIN; INDOMETACIN; INTERLEUKIN 6; MACROLIDE; PROSTAGLANDIN E2; ROXITHROMYCIN; TYLOSIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG MECHANISM; IN VITRO STUDY; LIPIDOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DINOPROSTONE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROLIDES; MACROPHAGES; MICE; PHOSPHOLIPIDS;

EID: 79959999337     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.03.011     Document Type: Article

References (27)

1. M.S. Whitman, and A.R. Tunkel Azithromycin and clarithromycin: overview and comparison with erythromycin Infect Control Hosp Epidemiol 13 6 1992 357 368
2. O. Culic, V. Erakovic, and M.J. Parnham Anti-inflammatory effects of macrolide antibiotics Eur J Pharmacol 429 1-3 2001 209 229 (Pubitemid 33043997)
3. M. Shinkai, M.O. Henke, and B.K. Rubin Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action Pharmacol Ther 117 3 2008 393 405
4. P.A. Crosbie, and M.A. Woodhead Long-term macrolide therapy in chronic inflammatory airway diseases Eur Respir J 33 1 2009 171 181
5. J. Zalewska-Kaszubska, and D. Gorska Anti-inflammatory capabilities of macrolides Pharmacol Res 44 6 2001 451 454 (Pubitemid 34014323)
6. A. Ianaro, A. Ialenti, P. Maffia, L. Sautebin, L. Rombola, and R. Carnuccio Anti-inflammatory activity of macrolide antibiotics J Pharmacol Exp Ther 292 1 2000 156 163 (Pubitemid 30026366)
7. D. Tyteca, P. Van Der Smissen, M. Mettlen, F. Van Bambeke, P.M. Tulkens, and M.P. Mingeot-Leclercq Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages Exp Cell Res 281 1 2002 86 100 (Pubitemid 35373785)
8. J.P. Montenez, F. Van Bambeke, J. Piret, R. Brasseur, P.M. Tulkens, and M.P. Mingeot-Leclercq Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models Toxicol Appl Pharmacol 156 2 1999 129 140 (Pubitemid 29196576)
9. F. Van Bambeke, C. Gerbaux, J.M. Michot, M.B. d'Yvoire, J.P. Montenez, and P.M. Tulkens Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin J Antimicrob Chemother 42 6 1998 761 767 (Pubitemid 29008078)
10. J. Mayne, A. Walsh, N. Johnson, A. Roesler, R. Shepard, and M. Tachibana Preclinical toxicology studies with azithromycin: acute and subchronic studies in rodents Oyo Yakuri: Pharmacometrics 51 2 1996 53 64
11. G. Lundeen, W. Milisen, R. Shepard, G. Foulds, A. Walsh, and S. Stadnicki Preclinical toxicology studies in beagle dogs with azithromycin Oyo Yakuri: Pharmacometrics 51 2 1996 65 74 (Pubitemid 26081377)
12. M. Bosnar, Z. Kelneric, V. Munic, V. Erakovic, and M.J. Parnham Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin Antimicrob Agents Chemother 49 6 2005 2372 2377 (Pubitemid 40734469)
13. V. Stepanic, S. Kostrun, I. Malnar, M. Hlevnjak, K. Butkovic, and I. Caleta Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties J Med Chem 54 2011 719 733
14. V. Munic, Z. Kelneric, L. Mikac, and V. Erakovic Haber Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays Eur J Pharm Sci 41 1 2010 86 95
15. K. Valko, C. Bevan, and D. Reynolds Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log P/log D Anal Chem 69 11 1997 2022 2029 (Pubitemid 127698689)
16. K. Valko, C.M. Du, C.D. Bevan, D.P. Reynolds, and M.H. Abraham Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures J Pharm Sci 89 8 2000 1085 1096
17. K. Valko, S. Nunhuck, C. Bevan, M.H. Abraham, and D.P. Reynolds Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity J Pharm Sci 92 11 2003 2236 2248 (Pubitemid 37356697)
18. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J Med Chem 45 12 2002 2615 2623 (Pubitemid 34595232)
19. M.H. Abraham, H.S. Chadha, F. Martins, R.C. Mitchell, M.W. Bradbury, and J.A. Gratton Hydrogen bonding part 46: a review of the correlation and prediction of transport properties by an LFER method: physicochemical properties, brain penetration and skin permeability Pesticide Sci 55 1 1999 78 88 (Pubitemid 29090796)
20. J.A. Platts, D. Butina, M.H. Abraham, and A. Hersey Estimation of molecular linear free energy relation descriptors using a group contribution approach J Chem Inform Comput Sci 39 5 1999 835 845
21. Y.H. Zhao, M.H. Abraham, A. Hersey, and C.N. Luscombe Quantitative relationship between rat intestinal absorption and Abraham descriptors Eur J Med Chem 38 11-12 2003 939 947 (Pubitemid 37452421)
22. J.L. Ferrero, B.A. Bopp, K.C. Marsh, S.C. Quigley, M.J. Johnson, and D.J. Anderson Metabolism and disposition of clarithromycin in man Drug Metab Dispos 18 4 1990 441 446 (Pubitemid 20220966)
23. P. Kurath, P.H. Jones, R.S. Egan, and T.J. Perun Acid degradation of erythromycin A and erythromycin B Experientia 27 4 1971 362
24. C. de Duve, T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. Van Hoof Commentary. Lysosomotropic agents Biochem Pharmacol 23 18 1974 2495 2531
25. M.B. Carlier, A. Zenebergh, and P.M. Tulkens Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells J Antimicrob Chemother 20 Suppl B 1987 47 56 (Pubitemid 18003048)
26. P.J. McDonald, and H. Pruul Phagocyte uptake and transport of azithromycin Eur J Clin Microbiol Infect Dis 10 10 1991 828 833
27. C. Seral, J.M. Michot, H. Chanteux, M.P. Mingeot-Leclercq, P.M. Tulkens, and F. Van Bambeke Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages Antimicrob Agents Chemother 47 3 2003 1047 1051 (Pubitemid 36254233)